- 主题
- 383
- 您的身份
- 病友
- 就诊医院
- 北京协和
- 病理报告
- 滤泡性淋巴瘤1-2级
- 目前状态
- 康复10-20年
参加活动:0 次 组织活动:0 次
您的身份病友
病理报告滤泡性淋巴瘤1-2级
就诊医院北京协和
目前状态康复10-20年
最后登录2025-5-17
  
|
发表于 2018-12-8 11:10:30
|
显示全部楼层
来自: 中国北京
来那度胺见效一点也不慢啊,有的人一个疗程就CR了。推荐的西达本胺不是见效慢不慢的问题,而是根本就没有任何证据能够穿过血脑屏障发挥作用的问题。另外,PD-1单抗对中枢神经系统淋巴瘤也有一定效果,在初步的临床试验中5位患者全部都有应答,其中3位实现了13到17个月的无进展生存。
Abstract
Primary central nervous system (CNS) lymphoma (PCNSL) and primary testicular lymphoma (PTL) are rare extranodal large B-cell lymphomas with similar genetic signatures. There are no standard-of-care treatment options for patients with relapsed and refractory PCNSL and PTL, and the overall prognosis is poor. PCNSLs and PTLs exhibit frequent 9p24.1 copy-number alterations and infrequent translocations of 9p24.1 and associated increased expression of the programmed cell death protein 1 (PD-1) ligands, PD-L1 and PD-L2. The activity of PD-1 blockade in other lymphomas with 9p24.1 alterations prompted us to test the efficacy of the anti–PD1 antibody, nivolumab, in 4 patients with relapsed/refractory PCNSL and 1 patient with CNS relapse of PTL. All 5 patients had clinical and radiographic responses to PD-1 blockade, and 3 patients remain progression-free at 13+ to 17+ months. Our data suggest that nivolumab is active in relapsed/refractory PCNSL and PTL and support further investigation of PD-1 blockade in these diseases. |
|